2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…2020 American Transplant Congress
The FcγRIIIa-158 VV Genotype Increased the Risk of Post-Transplant Lymphoproliferative Disorder in T-Cell Depleted Kidney Transplant Recipients
1CHU Tours, Tours, France, 2CHU Limoges, Limoges, France
*Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication in organ transplant recipients. The use of T lymphocyte-depleting antibodies (TLDAb), especially rabbit TLDAb contributes to…2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…2020 American Transplant Congress
Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients
*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…2020 American Transplant Congress
Comparison of Clinical Outcomes of Induction Regimens in Patients Undergoing Liver Transplantation for Acute Liver Failure
*Purpose: Spontaneous survival rates in acute liver failure (ALF) are vastly improved by liver transplantation (LT). However, the value of induction agents beyond steroids continues…2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 31
- Next Page »